<DOC>
	<DOC>NCT00848926</DOC>
	<brief_summary>This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.</brief_summary>
	<brief_title>A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with relapsed or refractory Hodgkin lymphoma who have previously received autologous stem cell transplant. Histologically confirmed CD30positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block. Fluorodeoxyglucoseavid disease by positron emission tomography and measurable disease of at least 1.5 cm as documented by spiral computed tomography. At US sites patients greater than or equal to 12 years of age may be enrolled. At nonUS sites patients must be greater than or equal to 18 years of age. Previous treatment with brentuximab vedotin. Previously received an allogeneic transplant. Congestive heart failure, Class III or IV, by the New York Heart Association criteria. History of another primary malignancy that has not been in remission for at least 3 years. Known cerebral/meningeal disease.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Antigens, CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Disease, Hodgkin</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethylauristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>